KOSPIBiotech & Pharma001060

JW Pharmaceutical

₩23,150▲ 0.65%2026-11-18 close
Market Cap
₩569.1B
Turnover
₩300M
Volume
10K
Shares out.
24.6M
PER
5.9×
PBR
1.3×
EPS
₩3,892
Dividend Yield
2.82%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩650 per share · Prices as of the 2026-11-18 close

01

Report overview

JW Pharmaceutical: original drug growth meets rising R&D costs

JW Pharmaceutical's original prescription drugs and IV fluids are driving revenue growth, while higher R&D spending pulled operating profit lower in the third quarter of 2026.

  1. 1

    Revenue in 2025 was KRW 775.3 billion, the largest of the 2022–2025 period, and operating profit rose 14.5% to KRW 94.5 billion.

  2. 2

    Third-quarter 2026 revenue of KRW 212.1 billion rose 6.0% year on year, but operating profit of KRW 29 billion fell 9.6%, extending a two-quarter decline that began in the second quarter.

  3. 3

    Multinational Phase 3 results for a gout candidate were released in August 2026, with a domestic approval filing planned for 2027. A three-drug combination candidate received clearance for a Phase 1 trial in October 2026.

  4. 4

    The corporate value-up plan disclosed in March 2026 set targets of a 30% dividend increase by 2027 and KRW 20 billion in share buybacks over three years.

  5. 5

    Controlling-shareholder net income for the four quarters from 4Q 2025 through 3Q 2026 totaled KRW 90.9 billion, and the share price sits above book equity.

02

Business structure

JW Pharmaceutical operates mainly through original prescription drugs (ETC), alongside IV fluids and over-the-counter (OTC) products. In the third quarter of 2026, preliminary figures released on November 4, 2026 showed ETC revenue of KRW 176.1 billion, or 83.4% of total sales.

Its flagship lipid-lowering drug Rivalo Jet generated KRW 30.9 billion in the quarter, up 16.6% year on year, and the Rivalo family combined reached KRW 53.1 billion, up 9.6%.

Sales of the hemophilia drug Hemlibra grew from KRW 5.8 billion in 2022 to KRW 72.6 billion in 2025, according to a Pharmnews report dated November 9, 2026.

IV fluid sales were KRW 73.5 billion in the third quarter of 2026 (preliminary), up 4.1%, and the segment comprises the Winuf multi-nutrient line, basic IV fluids and the Encover enteral nutrition product.

Production is handled by an affiliate's Dangjin plant, which reports an annual capacity of up to 122.2 million bag-type IV units and is described as the largest such facility in Korea.

The OTC segment recorded KRW 15.7 billion in the third quarter, up 18.0%, with the artificial tears brand Friends contributing KRW 7.2 billion, up 60.0%. Its customers are hospitals and pharmacies acting on physician prescriptions, so the business is exposed to prescribing trends and reimbursement drug pricing policy.

In 2026 the company was included among 18 supply-stability leading companies designated by the Ministry of Health and Welfare. On the expansion side, in September 2026 it acquired 100% of a biohealth venture capital firm for KRW 30.728 billion, broadening its access to external technologies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩200B₩32B16.0%
2025Q4₩198.9B₩15.5B7.8%
2026Q1₩199.9B₩33.6B16.8%
2026Q2₩222B₩33.3B15.0%
2026Q3₩212.1B₩29B13.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩684.4B₩63B₩31.9B9.2%13.3%178.2%
2023₩748.5B₩100.3B₩37B13.4%13.9%143.0%
2024₩719.4B₩82.5B₩65B11.5%19.7%83.5%
2025₩775.3B₩94.5B₩61.5B12.2%16.7%63.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 684.4 billion in 2022 to KRW 775.3 billion in 2025, and 2025 was the largest year of the 2022–2025 period. Revenue grew 9.4% in 2023 to KRW 748.5 billion, fell 3.9% in 2024 to KRW 719.4 billion, then rose 7.8% in 2025.

Operating profit went from KRW 63 billion in 2022 to KRW 100.3 billion in 2023, up 59.3%, which was the largest year of the period, then fell 17.8% to KRW 82.5 billion in 2024.

Operating profit recovered 14.5% to KRW 94.5 billion in 2025, and the operating margin was 9.2% in 2022, 13.4% in 2023, 11.5% in 2024 and 12.2% in 2025.

Controlling-shareholder net income rose from KRW 31.9 billion in 2022 to KRW 37 billion in 2023 and KRW 65 billion in 2024, up 75.8%, before falling 5.4% to KRW 61.5 billion in 2025.

In 2022, net income including non-controlling interests (KRW 29.9 billion) was below controlling-shareholder net income (KRW 31.9 billion), which means the non-controlling share was a loss. In 2024 and 2025, total net income matched controlling-shareholder net income at KRW 65 billion and KRW 61.5 billion.

The debt-to-equity ratio fell from 178.2% in 2022 to 63.9% in 2025, and at the end of 2025 total equity was KRW 369.4 billion against total liabilities of KRW 235.9 billion. Operating cash flow rose from KRW 56.8 billion in 2022 to KRW 96.4 billion in 2025.

Quarterly operating profit went from KRW 32 billion in the third quarter of 2025 to KRW 15.5 billion in the fourth quarter, down 51.7%, then recovered to KRW 33.6 billion in the first quarter of 2026, up 117.2%, which was the peak.

It then declined for two consecutive quarters, to KRW 33.3 billion in the second quarter (down 0.7%) and KRW 29 billion in the third (down 13.2%), even as third-quarter revenue of KRW 212.1 billion rose 6.0% year on year.

In its November 4, 2026 preliminary disclosure, the company attributed the operating profit decline mainly to higher R&D spending. Controlling-shareholder net income was KRW 20.2 billion in the third quarter of 2026, down 34.0% year on year, and the four quarters from 4Q 2025 through 3Q 2026 totaled KRW 90.9 billion.

05

Industry analysis

Korea's pharmaceutical sector is a competition among improved new drugs, the in-licensing and sales of original drugs, and in-house new drug development.

JW Pharmaceutical started out by importing and selling overseas original drugs and is reported to be channeling those earnings into in-house drug development and external biotech technologies.

Within the same sector, Celltrion and Samsung Biologics are centered on biopharmaceutical manufacturing and development, while Yuhan and Hanmi Pharm tend to put more weight on their own new drug pipelines.

With ETC accounting for 83.4% of third-quarter 2026 revenue on a preliminary basis, JW Pharmaceutical's earnings structure is clearly centered on prescription drugs.

Its IV fluid business relies on the large-scale Dangjin plant for supply stability, and its inclusion among 18 supply-stability leading companies in 2026 fits that role. IV fluid sales growth slowed from a preliminary 13.7% in the second quarter of 2026 to 4.1% in the third quarter.

In new drugs, the company is spreading investment across gout, obesity and diabetes, and combination products, so the timing at which each pipeline's clinical results reach earnings differs by product.

Comparing its position with peers only becomes meaningful when pipeline stage and product-level revenue mix are measured on the same basis.

06

Outlook

In its March 27, 2026 corporate value-up plan, the company set a target of a 3-year revenue compound annual growth rate (CAGR) of 10% or more through 2027. Revenue grew 7.8% in 2025, so reaching the target would require sustained double-digit-level revenue expansion in 2026 and 2027.

The Phase 1 trial for the three-drug combination candidate JW0113, which pairs pitavastatin and ezetimibe with a diabetes agent, is scheduled to begin in December 2026 with 64 healthy adults.

For the gout candidate, the multinational Phase 3 trial enrolled 612 patients across 52 medical institutions in five countries, with topline results released in August 2026, and the company plans a domestic approval filing in 2027 based on the 6 mg dose.

The product was selected for a Ministry of Food and Drug Safety pilot program on approval and review innovation, and it held two pre-filing consultations before the July 2026 submission plan.

In obesity and diabetes, the company filed in August 2026 for domestic Phase 3 trial plans for an candidate in-licensed from China's Gan & Lee Pharmaceuticals, covering 300 adults with obesity and 174 with type 2 diabetes.

Its shareholder return plan targets a 30% dividend increase by 2027, KRW 20 billion in share buybacks over three years, and a payout ratio of about 25% on a consolidated basis through 2028. The 2026 annual report, the next periodic filing, is the next checkpoint for the full-year operating margin and capital structure.

07

Valuation

PER
5.9×
PBR
1.3×
ROE
23.3%
EPS
₩3,892
BPS
₩18,418
Dividend per share
₩650

The share price sits above book equity, meaning it trades at a premium to net asset value, with total equity at KRW 369.4 billion. Because market capitalization exceeds book equity, the market price reflects expectations for earnings growth and pipeline value.

On earnings, controlling-shareholder net income fell from KRW 65 billion in 2024 to KRW 61.5 billion in 2025, and the four quarters from 4Q 2025 through 3Q 2026 totaled KRW 90.9 billion.

Operating profit declined year on year in the third quarter of 2026, so multiple comparisons need to be read alongside the earnings trend.

The dividend policy targets a 30% increase in dividends by 2027 and a consolidated payout ratio of about 25% by 2028, and the company disclosed that it qualifies as a high-dividend company.

Where the current multiple sits within its past trading band and how it compares with the sector average are comparisons that move with the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

A revenue base built on original drugs

Rivalo Jet reached KRW 30.9 billion in preliminary third-quarter 2026 sales, up 16.6% year on year, and the Rivalo family totaled KRW 53.1 billion. Hemlibra sales grew from KRW 5.8 billion in 2022 to KRW 72.6 billion in 2025. IV fluids and the Friends OTC brand also grew in the same quarter, so the revenue mix spans several segments.

Pipeline advancing through stages

Multinational Phase 3 results for the gout candidate were disclosed in August 2026, and a domestic filing at the 6 mg dose is planned for 2027. A U.S. dosing patent has been registered, securing a patent base through 2038.

The three-drug combination candidate JW0113 received Phase 1 trial clearance in October 2026 and is scheduled to start in December 2026.

Shareholder return targets set out

The corporate value-up plan disclosed on March 27, 2026 set targets of a 30% dividend increase by 2027 and KRW 20 billion in buybacks over three years. The company disclosed that it bought back KRW 5 billion of shares in 2025.

It targets a consolidated payout ratio of about 25% through 2028 and said it qualifies as a high-dividend company.

09

Bear factors

Operating profit decline in the third quarter

Third-quarter 2026 operating profit of KRW 29 billion fell 9.6% year on year, and the decline has now lasted two consecutive quarters. In its November 4, 2026 preliminary disclosure, the company cited higher R&D spending as the main factor. Controlling-shareholder net income of KRW 20.2 billion fell 34.0% year on year in the same quarter.

Limited profitability levels

The operating margin fell from 13.4% in 2023 to 11.5% in 2024 and recovered to 12.2% in 2025, still below the 2023 level. Controlling-shareholder net income fell 5.4% to KRW 61.5 billion in 2025 from KRW 65 billion in 2024. Revenue growth has translated into limited profit growth.

R&D burden and clinical uncertainty

The obesity and diabetes candidate is at the stage of a domestic Phase 3 trial filing made in August 2026, and the combination product's Phase 1 start is set for December 2026. New drug timelines and costs can shift with clinical results.

Fourth-quarter 2025 operating profit of KRW 15.5 billion fell 51.7% from the prior quarter, underscoring quarterly volatility.

10

Risk factors

Policy and reimbursement pricing risk

ETC accounts for 83.4% of revenue on a preliminary third-quarter 2026 basis, so earnings are sensitive to drug price adjustments and prescribing policy. IV fluids are linked to government supply policy through the supply-stability leading company designation. Changes in product-level reimbursement prices would directly affect sales of the Rivalo family and Hemlibra.

Pipeline clinical and approval risk

The domestic approval filing for the gout candidate is planned for 2027, and the obesity and diabetes candidate is in domestic Phase 3 planning. If clinical results or approval timelines slip, R&D costs could keep weighing on profit. The third-quarter 2026 operating profit decline is tied to the expansion of R&D spending.

Product concentration and earnings volatility

Growth is led by a few original products such as the Rivalo family and Hemlibra, so competing products or patent expiry could materially affect results. Quarterly operating profit swung from KRW 15.5 billion in 4Q 2025 to KRW 33.6 billion in 1Q 2026. Because quarter-to-quarter swings are large, the trend is hard to read from a single quarter.

11

What to watch next

  1. December 2026

    The Phase 1 trial of the three-drug combination candidate JW0113 is scheduled to start in 64 healthy adults. It is the first signal of how fast the pipeline is moving.

  2. Around January–February 2027 (estimated from prior disclosure timing)

    Preliminary fourth-quarter and full-year 2026 results are due. Whether fourth-quarter operating profit moves from the third-quarter level of KRW 29 billion will confirm whether the two-quarter decline continues.

  3. By the end of March 2027

    This is the filing deadline for the 2026 annual report. It will set out the full-year operating margin and progress on the dividend and buyback commitments in the value-up plan.

  4. During 2027

    Whether the domestic marketing approval application for the gout candidate is actually filed, and how the Ministry of Food and Drug Safety review progresses, marks the next milestone for commercialization.

12

Overall view

JW Pharmaceutical is a drugmaker whose revenue, built around original prescription drugs and IV fluids, rose from KRW 684.4 billion in 2022 to KRW 775.3 billion in 2025. Operating profit grew 14.5% to KRW 94.5 billion in 2025, and the debt-to-equity ratio fell to 63.9% at the end of 2025.

By contrast, third-quarter 2026 disclosed results showed revenue of KRW 212.1 billion, up 6.0% year on year, and operating profit of KRW 29 billion, down 9.6%, with profit declining for two consecutive quarters from the second quarter.

Strengths include revenue growth from original products such as Rivalo Jet and Hemlibra, steady IV fluid and OTC sales, the planned 2027 gout filing, and shareholder return targets.

Weaknesses include the operating profit decline from higher R&D spending, the 5.4% drop in 2025 controlling-shareholder net income, and dependence on clinical outcomes and drug pricing policy.

The company's medium-term target is a revenue CAGR of 10% or more through 2027, and the gap with actual revenue can be checked in periodic filings after 2027.

The next checkpoints are the start of the combination Phase 1 trial in December 2026, preliminary results in early 2027, and the 2026 annual report by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharmnews.com
  2. fnnews.com
  3. m.news.nate.com
  4. etoday.co.kr
  5. jw-pharma.co.kr
  6. m.news.nate.com
  7. dealsite.co.kr
  8. m.news.nate.com
  9. m.news.nate.com
  10. pinpointnews.co.kr
  11. ebn.co.kr
  12. supple.kr
  13. alphabiz.co.kr
  14. sentv.co.kr
  15. seoulfn.com
  16. supple.kr
  17. news.bizwatch.co.kr
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis